1. "2011"
Formats
  1. Journal Article (2141)
  2. Meeting Abstract (988)
  3. Book Section (224)
  4. Conference Paper (18)
  5. Book Whole (11)
Groups
  1. Department of Medicine (1176)
  2. Surgery (803)
  3. GSK Faculty (796)
  4. Solid Tumor Oncology Division (659)
  5. Sloan Kettering Institute Faculty (606)
  6. Survivorship Research (542)

More Groups

People
  1. Robert Soslow (64)
  2. Clifford Hudis (60)
  3. Mithat Gonen (54)
  4. Marc Ladanyi (52)
  5. Robert Motzer (52)
  6. Valerie Rusch (47)

More People

Years
  1. 2011 (3382)
Publications
  1. Journal of Clinical Oncology (319)
  2. Blood (147)
  3. Cancer Research (122)
  4. International Journal of Radiation Oncology, Biology, Physics (104)
  5. Modern Pathology (70)
  6. Laboratory Investigation (65)

More Publications

Publishers
  1. Elsevier Inc. (450)
  2. American Society of Clinical Oncology (327)
  3. Springer (231)
  4. American Association for Cancer Research (180)
  5. Nature Publishing Group (157)
  6. Wiley Blackwell (154)

More Publishers

Results (3382)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103
    Meeting Abstract

    Schneider, B. P.; Li, L.; Miller, K.; Flockhart, D.; Radovich, M.; Hancock, B. A.; Kassem, N.; Foroud, T.; Koller, D. L.; Badve, S. S.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A US and European international collaborative analysis
    Meeting Abstract

    Shah, M. A.; Janjigian, Y. Y.; Pauligk, C.; Werner, D.; Kelsen, D. P.; Jaeger, E.; Altmannsberger, H.; Robinson, E.; Tang, L. H.; Barbashina, V. V.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Riely, G. J.; Gettinger, S. N.; Stoller, R. G.; Gabrail, N. Y.; Dy, G. K.; Weiss, G. J.; Tunkey, C.; Skliris, G.; Strychor, S.; Dunbar, J.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Survivorship care plans for colorectal cancer survivors: What do primary care providers want and need?
    Meeting Abstract

    Salz, T.; Oeffinger, K. C.; Lewis, P. R.; Rhyne, R.; Williams, R. L.; Yeazel, M. W.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial
    Meeting Abstract

    Rini, B. I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Hutson, T. E.; Szczylik, C.; Tarazi, J. C.; Rosbrook, B.; Kim, S.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Comparison of outcomes of intensity-modulated radiotherapy and 3-D conformal radiotherapy for anal squamous cell carcinoma using a propensity score analysis
    Meeting Abstract

    Rothenstein, D. A.; Dasgupta, T.; Chou, J. F.; Zhang, Z.; Wright, J. L.; Temple, L. K. F.; Saltz, L.; Goodman, K. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Saad, F.; Akaza, H.; Eisenberger, M. A.; Nelson, J.; Scher, H. I.; Suzuki, K.; Wirth, M.; Webb, I. J.; Wang, J.; MacLean, D.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT)
    Meeting Abstract

    Ratain, M. J.; Schwartz, G. K.; Oza, A. M.; Rudin, C. M.; Kaye, S. B.; De Jonge, M. J.; Khayat, D.; Awada, A.; Sawyer, M. B.; Obel, J. C.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save